References
- Liu Y , SethiNS , HinoueTet al. Comparative molecular analysis of gastrointestinal adenocarcinomas. Cancer Cell33(4), 721–735.e728 (2018).
- Siegel RL , MillerKD , JemalA. Cancer statistics, 2020. CA Cancer J. Clin.70(1), 7–30 (2020).
- D’errico M , AlwersE , ZhangY , EdelmannD , BrennerH , HoffmeisterM. Identification of prognostic DNA methylation biomarkers in patients with gastrointestinal adenocarcinomas: A systematic review of epigenome-wide studies. Cancer Treat. Rev.82, 101933 (2020).
- Powell AGMT , SoulS , ChristianA , LewisWG. Meta-analysis of the prognostic value of CpG island methylator phenotype in gastric cancer. Br. J. Surg.105(2), e61–e68 (2018).
- Namba S , SatoK , KojimaSet al. Differential regulation of CpG island methylation within divergent and unidirectional promoters in colorectal cancer. Cancer Sci.110(3), 1096–1104 (2019).
- Ning B , LiW , ZhaoW , WangR. Targeting epigenetic regulations in cancer. Acta Biochim. Biophys. Sin.48(1), 97–109 (2016).
- Pan Y , LiuG , ZhouF , SuB , LiY. DNA methylation profiles in cancer diagnosis and therapeutics. Clin. Exp. Med.18(1), 1–14 (2018).
- Lee H , PalmJ , GrimesSM , JiHP. The Cancer Genome Atlas Clinical Explorer: a web and mobile interface for identifying clinical-genomic driver associations. Genome Med.7, 112 (2015).
- Yang X , GaoL , ZhangS. Comparative pan-cancer DNA methylation analysis reveals cancer common and specific patterns. Brief. Bioinform.18(5), 761–773 (2017).
- Bibikova M , BarnesB , TsanCet al. High density DNA methylation array with single CpG site resolution. Genomics98(4), 288–295 (2011).
- Pan Y , SongY , ChengL , XuH , LiuJ. Analysis of methylation-driven genes for predicting the prognosis of patients with head and neck squamous cell carcinoma. J. Cell. Biochem.120(12), 19482–19495 (2019).
- Gevaert O . MethylMix: an R package for identifying DNA methylation-driven genes. Bioinformatics31(11), 1839–1841 (2015).
- Wolbers M , KollerMT , WittemanJC , SteyerbergEW. Prognostic models with competing risks: methods and application to coronary risk prediction. Epidemiology20(4), 555–561 (2009).
- Yu G , WangLG , HanY , HeQY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS16(5), 284–287 (2012).
- Kanwal R , GuptaS. Epigenetic modifications in cancer. Clin. Genet.81(4), 303–311 (2012).
- Sanford T , MengMV , RailkarR , AgarwalPK , PortenSP. Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma. Clin. Epigenetics10, 19 (2018).
- Lofton-Day C , LescheR. DNA methylation markers in patients with gastrointestinal cancers. Current understanding, potential applications for disease management and development of diagnostic tools. Dig. Dis.21(4), 299–308 (2003).
- Luo H , ZhaoQ , WeiWet al. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci. Transl. Med.12(524), 10.1126/scitranslmed.aax7533(2020).
- Fang W-L , ChenM-H , HuangK-Het al. Analysis of the clinical significance of DNA methylation in gastric cancer based on a genome-wide high-resolution array. Clin. Epigenetics11(1), 154 (2019).
- Baylin SB , JonesPA. A decade of exploring the cancer epigenome – biological and translational implications. Nat. Rev. Cancer11(10), 726–734 (2011).
- Dai D , ZhouB , XuW , JinH , WangX. CHFR promoter hypermethylation is associated with gastric cancer and plays a protective role in gastric cancer process. J. Cancer10(4), 949–956 (2019).
- Jiang H , SunL , HuC , WangY. Hypermethylated and its clinical significance in colorectal cancer. Am. J. Transl. Res.10(12), 4290–4301 (2018).
- Li D , BaiY , FengZet al. Study of promoter methylation patterns of HOXA2, HOXA5, and HOXA6 and its clinicopathological characteristics in colorectal cancer. Front. Oncol.9, 394 (2019).
- Ieta K , TanakaF , YokoboriTet al. Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer. Int. J. Cancer125(4), 926–931 (2009).
- Zhai J , YangZ , CaiXet al. ZNF280B promotes the growth of gastric cancer and. Oncol. Lett.15(4), 5819–5824 (2018).
- Wan X-B , WangA-Q , CaoJet al. Relationships among mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer. World J. Gastroenterol.25(7), 808–823 (2019).
- Soleimani A , RahmaniF , SaeediNet al. The potential role of regulatory microRNAs of RAS/MAPK signaling pathway in the pathogenesis of colorectal cancer. J. Cell. Biochem.120(12), 19245–19253 (2019).
- Jia H , XuM , BoY , LiW , ZhouR. Ras-ERK1/2 signaling accelerates the progression of colorectal cancer via mediation of H2BK5ac. Life Sci.230, 89–96 (2019).
- Stevens PD , WenY-A , XiongXet al. Erbin suppresses KSR1-mediated RAS/RAF signaling and tumorigenesis in colorectal cancer. Cancer Res.78(17), 4839–4852 (2018).
- Kumar S , AgnihotriN. Piperlongumine, a piper alkaloid targets Ras/PI3K/Akt/mTOR signaling axis to inhibit tumor cell growth and proliferation in DMH/DSS induced experimental colon cancer. Biomed. Pharmacother.109, 1462–1477 (2019).
- Boutin AT , LiaoW-T , WangMet al. Oncogenic drives invasion and maintains metastases in colorectal cancer. Genes Dev.31(4), 370–382 (2017).